close
MENU
Hot Topic EARNINGS
How to guide
How to guide
Home
The NBR Rich List
NBR Marketplace
NBR Video

Categories

General Business Investment Economics Te Ao Māori Politics Infrastructure Australia Tech & Innovation Finance Law Professional Services Primary Industries Retail Property Deals Marketing & Media Tourism Energy Luxury Property Aviation News Comings & Goings

Analysis

All Economy Matters Edwards on Politics Hunter’s Corner Last Word Margin Call On the Money Shoeshine Underarm NBR Focus

Featured

NBR Marketplace Local Edge NBR Video Toil & Trouble Beehive Banter Morning Brew Dollars & Sense Entrepreneurs The Grind Market Outlook Executive Health Market Review Students’ Say The NBR Podcast Opinion (Archive) NBR Radar (Archive) Private Bin NZ Aviation News (Archive) NBR Rich List (Archive) Your Business Audio Articles The NBR Rich List
Hot Topic EARNINGS
The Grind
7 mins to read
1

Biotech chemist Iona Weir has a cunning GMP manufacturing plan

Following successful clinical trials, her R&D discovery company is hoping to exit via big pharma.

Brand ambassador Robyn Malcolm and Weir Science founder Iona Weir.

Fiona Rotherham Fri, 18 Jul 2025
Key points
  • What's at stake: Entrepreneurial scientist Iona Weir hopes she and her backers can exit Weir Science to a big pharma buyer after successful clinical trials on her hero ingredient Myrecil, which treats women who have Genitourinary Syndrome of Menopause (GSM).
  • Background: Weir applied to human cells her scientific know-how on reversing cell death in plants, developing a patented skincare range. She is now seeing FDA approval for its use for GSM. She needs to upgrade to GMP manufacturing to interest pharma buyers.
  • Key players: Iona Weir, Weir Science, FDA, Daniel Barnes, Paul Dallimore, John Kitto.

One of the most famous quotes from the long-running BBC comedy series Blackadder is when Edmund Blackadder’s sidekick Baldrick says: “My Lord, I have a cunning plan.”

So, too, does Kiwi scientist and company CEO Dr Iona Weir. Her company, Weir Science, recently successfully completed a

Want to read more? It's easy.

Choose your subscription

Already have an account? Login

Smartphone Only Subscription

NZ$29.95 / monthly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Yearly Premium Online Subscription

NZ$499.00 / yearly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$999.00 / yearly

Individual
Group membership
NBR Marketplace

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
View terms and conditions.
Fiona Rotherham Fri, 18 Jul 2025
Contact the Writer: fiona@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Tags
Dr Iona Weir Weir_Science science and innovation FDA

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Related News

BioNona gains FDA approval for Atopis eczema cream, plans to start online US sales
The Grind
4

How Urgent Couriers is adapting to the loss of a major client
The Grind
8

‘It’s f***ing hard’ : 20 years of Good as Gold

Bionona sticks to online sales in launch of eczema treatment
1

Decima Health to pitch eczema treatment at US conference

Free News Alerts

Sign up to get the latest stories and insights delivered to your inbox – free, every day.

I’m already subscribed/joined
Key points
  • What's at stake: Entrepreneurial scientist Iona Weir hopes she and her backers can exit Weir Science to a big pharma buyer after successful clinical trials on her hero ingredient Myrecil, which treats women who have Genitourinary Syndrome of Menopause (GSM).
  • Background: Weir applied to human cells her scientific know-how on reversing cell death in plants, developing a patented skincare range. She is now seeing FDA approval for its use for GSM. She needs to upgrade to GMP manufacturing to interest pharma buyers.
  • Key players: Iona Weir, Weir Science, FDA, Daniel Barnes, Paul Dallimore, John Kitto.
Related News

BioNona gains FDA approval for Atopis eczema cream, plans to start online US sales
The Grind
4

How Urgent Couriers is adapting to the loss of a major client
The Grind
8

‘It’s f***ing hard’ : 20 years of Good as Gold

Bionona sticks to online sales in launch of eczema treatment
1

Decima Health to pitch eczema treatment at US conference
Biotech chemist Iona Weir has a cunning GMP manufacturing plan
The Grind,General Business,
110076
true
Subscribe Login